CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. (2002)
Corbascio, Matthias, Ekstrand, Helene, Osterholm, Cecilia, Qi, Zhongquan, Simanaitis, Mecislovas, Larsen, Christian P, ...
CTLA4Ig and anti-LFA-1 are members of a new generation of immunomodulatory drugs which inhibit important signaling pathways in T cell activation. Both substances target molecules which have pivitol...